MarketPulse

sublingual film

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

AQST Investors Face May 4 Deadline in Securities Fraud Lawsuit Over Anaphylm Claims

Aquestive Therapeutics ($AQST) investors have until May 4, 2026 to join a securities fraud lawsuit alleging the company concealed human factors issues with its Anaphylm sublingual film product.
AQSTsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

AQST Investors Face May 4 Deadline in Securities Lawsuit Over Anaphylm NDA Issues

Rosen Law Firm alerts AQST investors of May 4, 2026 deadline to join class action alleging Aquestive Therapeutics concealed human factors issues with its Anaphylm drug application.
AQSTsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Class Action Filed Against Aquestive Therapeutics Over Anaphylm Drug Application Disclosures

Rosen Law Firm files securities class action against $AQST over alleged misleading statements regarding its Anaphylm drug application between June 2025 and January 2026.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aquestive to Unveil Anaphylm Clinical Results at 2026 Allergy Conference

Aquestive to present clinical trial data for Anaphylm, an investigational oral anaphylaxis treatment, at 2026 allergy conference, showing promising safety and efficacy results.
AQSTclinical dataFDA approval